Expression of ER, PR, and Her-2/neu in endometrial cancer: A clinicopathological study

Asian Pacific Journal of Cancer Prevention

Volumn 11, Issue 1, 2010, Pages 215-220

  Srijaipracharoen, Sunamchok ^a   Tangjitgamol, Siriwan ^a   Tanvanich, Sujitra ^a   Manusirivithaya, Sumonmal ^a   Khunnarong, Jakkapan ^a   Thavaramara, Thaovalai ^a   Leelahakorn, Surawute ^a   Pataradool, Kamol ^a  

^a Bangkok Metropolitan Administration   (Thailand)

Author keywords

Endometrial carcinoma; ER and PR expression; Her 2 neu status

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PARAFFIN; PROGESTERONE RECEPTOR;

ENDOMETRIUM TUMOR; ENZYME IMMUNOASSAY; FEMALE; HUMAN; METABOLISM; MIDDLE AGED; MORTALITY; MYOMETRIUM; PATHOLOGY; SURVIVAL RATE; TUMOR INVASION;

ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MIDDLE AGED; MYOMETRIUM; NEOPLASM INVASIVENESS; PARAFFIN EMBEDDING; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SURVIVAL RATE;

EID: 77955815951     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Benedetti Panici P, Basile S, Maneschi F, et al (2008). Systematic pelvic lymphadenectomy vs no lymphadenectomy in earlystage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst, 100, 1707-16.
2. Berchuck A, Rodriguez G, Kinney RB, et al (1991). Overexpression of HER-2/neu in endometrial cancer in associated with advanced stage disease. Am J Obstet Gynecol, 164, 15-21.
3. Bigsby RM, Li AX, Bomalaski J, et al (1992). Immunohistochemical study of HER-2/neu, epidermal growth factor receptor, and steroid receptor expression in normal and malignant endometrium. Obstet Gynecol, 79, 95-100.
4. Carcangiu ML, Chambers JT, Voynick IM, Schwartz PE (1990). Immunohistochemical evaluation of estrogen and progesterone receptor content in 183patients with endometrial carcinoma. Part I: clinical and histologic correlations. Am J Clin Pathol, 94, 247-54.
5. Chan JK, Cheung MK, Kuh WK, et al (2006). Therapeutic role of lymph node resection in endometrioid corpus cancer. Cancer, 107, 1823-30.
6. Chearskul S, Bhothisuwan K, Ornrhebroi S, et al (2000). Serum c-erbB-2 protein in breast cancer patients. J Med Assoc Thai, 83, 886-93.
7. Coronado PJ, Vidart JA, Lopez-Asenjo JA (2001). p53 overexpression predicts endometrial carcinoma recurrent better than HER2/neu overexpression. Eur J Obstet Gynecol Reprod Biol, 98, 103-8.
8. Creasman WT, Soper JT, McCarty KS Jr, et al (1985). Influence of cytoplasmic steroid receptor content on prognosis of early stage endometrial carcinoma. Am J Obstet Gynecol, 151, 922-32.
9. Creutzberg CL, van Putten WL, Koper PC, et al (2000). Surgery and postoperative radiotherapy versus surgery alone for patients with stage 1 endometrial carcinoma: multicentre randomized trial.PORTEC Study group. Postoperative radiation therapy in endometrial carcinoma. Lancet, 355, 1404-11.
10. Decruze SB, Green JA (2007). Hormone therapy in advanced and recurrent endometrial cancer: a systematic review. Int J Gynecol Cancer, 17, 964-78.
11. Ehrlich CE, Peter CM, Stheman FB, Sutton GP, Alford WM (1988). Steroid receptors and clinical outcome in patients with adenocarcinoma of the endometrium. Am J Obstet Gynecol, 158, 796-807.
12. Engelsen IB, Stefansson IM, Beroukhim R, et al (2008). Her-2/neu expression is associated with high tumor cell proliferation and aggression phenotype in population based patient series of endometrial carcinomas. Int J Oncol, 32, 307-16.
13. Fukuda K, Mori M, Uchiyama M, et al (1998).Prognostic significance of progesterone receptor immunohistochemistry in endometrial carcinoma. Gynecol Oncol, 69, 220-5.
14. Gal D, Recio FO, Zamurovic D, Tancer ML (1991). Lymphovascular space involvement-a prognostic indicator in endometrial adenocarcinoma. Gynecol Oncol, 42, 142-5.
15. Gassel AM, Backe J, Krebs S, et al (1998). Endometrial carcinoma: immunohistochemically detected proliferation index is a prognosticator of long-term outcome. J Clin Pathol, 51, 25-9
16. Gehrig PA, Van Le L, Olatidoye B, Geradts J (1999). Estrogen receptor status, determined by immunohistochemistry, as a predictor of the recurrence of stage I endometrial carcinoma. Cancer, 86, 2083-9.
17. Goldhirsch A, Ingle JN, Gelber RD, et al (2009). Thresholds for therapies: highlights of the St Gallen International Expert consensus on the primary therapy of early breast cancer 2009. Ann Oncol, 20, 1319-29.
18. Hamel MW, Sebo TJ, Wilson TO, et al (1996). Prognostic value of p53 and proliferating cell nuclear antigen expression in endometrial carcinoma. Gynecol Oncol, 62, 192-8.
19. Hanekamp EE, Gielen SCJP, Smid-Koopman E, et al (2003). Consequences of loss of progesterone receptor expression in development of invasive endometrial cancer. Clin Cancer Res, 9, 4190-9.
20. Heintz NH, Leslie KO, Rogers LA, Howard PL (1990). Amplificationof the c-erbB-2 oncogene and prognosis of breast adenocarcinoma. Arch Pathol Lab Med, 114, 160-3.
21. Hetzel DJ, Wilson TO, Keeney GL, et al (1992). HER-2/neu expression: a major prognostic factor in endometrial cancer. Gynecol Oncol, 47, 179-85.
22. Iversen OE, Utaaker E, Skaarland E (1998). DNA ploidy steroid receptors as predictors of disease course in patients with endometrial carcinoma. Acta Obstet Gynecol Scand, 67, 531-7.
23. Iwai K, Fukuda K, Hachisuga T, et al (1999). Prognostic significance of progesterone receptor immunohistochemistry for lymph node metastases in endometrial carcinoma.Gynecol Oncol, 72, 351-9.
24. Jeon YT, Park IA, Kim YB, et al (2006). Steroid receptor expressions in endometrial cancer: Clinical significance and epidemiological implication. Cancer Lett, 239, 198-204.
25. Jongen V, Briet J, Jong RD, et al (2009). Expression of estrogen receptor-alpha and-beta and progesterone receptor-A and - B in a large cohort of patients with endometrioid endometrial cancer. Gynecol Oncol, 112, 537-42.
26. Keys HM, Roberts JA, Brunetto VL (2004). A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial carcinoma: Gynecologic Oncology Group Study. Gynecol Oncol, 92, 744-51.
27. Khalifa MA, Mannel RS, Haraway SD, Walker J, Min KW (1994). Expression of EGFR, HER-2/neu, p53 and PCNA in endometrioid, serous papillary and clear cell endometrial adenocarcinomas. Gynecol Oncol, 3, 84-92.
28. Kitchener H, Swart AM, Qian Q, Amos C, Parmar MK (2009). Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet, 373, 125-36.
29. Kleine W, Maier T, Geyer H, Pfleiderer A (1990). Estrogen and progesterone receptors in endometrial cancer and their prognostic relevance. Gynecol Oncol, 38, 59-65.
30. Klijanienko J, Couturier J, Galut M, et al (1999). Detection and quantitation by fluorescence in situ hybridization FISH and image analysis of her2 neu gene amplification in breast cancer fine-needle samples. Cancer, 87, 312-8.
31. Kodama J, Seki N, Hiramatsu Y (2007). Chemotherapy for highrisk early-stage endometrial cancer. Curr Opin Obstet Gynecol, 19, 42-7.
32. Luke AS, Kohler MF, Pieper CF, et al (1994). Multivariable analysis of DNA ploidy, p53, and HER-2/neu as prognostic factors in endometrial cancer. Cancer, 73, 2380-5.
33. Miyamoto T, Watanabe J, Hata H, et al (2004). Significant of progesterone receptor-A and B expressions in endometrial adenocarcinoma. J Steroid Biochem Molec Biol, 92, 111-8.
34. Morris PC, Anderson JR, Anderson B, Buller RE (1995). Steroid hormone receptor content and lymph node status in endometrial cancer. Gynecol Oncol, 56, 406-11.
35. Mutch DG, Soper JT, Budwit-Novotny DA, et al (1987). Endometrial adenocarcinoma estrogen receptor content: association of clinicopathologic features with immunohistochemical analysis compared with standard biochemical methods. Am J Obstet Gynecol, 157, 924 -31.
36. Niederacher D, An HX, Cho YJ, et al (1999). Mutations and amplification of oncogenes in endometrial cancer. Oncology, 56, 59-65.
37. Nyholm HC, Nielsen AL, Lyndrup J, Norup P, Thorpe SM (1992). Biochemical and immunohistochemical estrogen and progesterone receptors in adenomatous hyperplasia and endometrial carcinoma: correlations with stage and other clinicopathological features. Am J Obstet Gynecol, 167, 1334-42.
38. Nyholm HC, Neilsen AL, Lyndrup J, Dreisler A, Thorpe SM (1993). Estrogen and progesterone receptors in endometrial carcinoma: comparison of immunohistochemical and biochemical analysis. Int J Gynecol Pathol, 12, 246-52.
39. Palmer DC, Muir IM, Alexander AI, et al (1988). The prognostic importance of steroid receptors in endometrial carcinoma. Obstet Gynecol, 72, 388-93.
40. Parkin DM, Bray F, Ferlay J, Pisani P (2005). Global cancer statistics, 2002. CA Cancer J Clin, 55, 74-108.
41. Pisani AL, Barbuto DA, Chen D, et al (1995). HER-2/neu, p53, and DNA analyses as prognosticators for survival in endometrial carcinoma. Obstet Gynecol, 85, 729-34.
42. Ravdin PM, Chamness GC (1995). The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: a paradigm for the development of other macromolecular markers-a review. Gene, 159, 19-27.
43. Revillion F, Bonneterre J, Peyrat JP (1998). ERBB2 oncogene in human breast cancer and its clinical significance. Eur J Cancer, 34, 791-808.
44. Saffari B, Jones LA, El-Naggar A, et al (1995). Amplification and overexpression of HER- 2/neu (c-erbB2) in endometrial cancer: correlation with overall survival. Cancer Res, 55, 5693-8.
45. Sivridis E, Giatromanolaki A, Koukourakis M, Anastasiadis P (2001). Endometrial carcinoma: association of steroid hormone receptor expression with low angiogenesis and bcl-2 expression. Virchows Arch, 438, 470-7.
46. Slamon DJ, GodolphinW, Jones LA, et al (1989). Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science, 244, 707-12.
47. Snijders MP, De Goeij AF, Koudstaal J, et al (1990). Is immunohistochemical analysis of oestrogen and progesterone receptors in endometrial carcinoma superior to the radioligand binding assay? J Pathol, 161, 129-35.
48. Suthipintawong C, Wejaranayang C, Vipupinyo C (2008). Prognostic significance of ER, PR, KI-67, c-erbB-2, and p53 in endometrial carcinoma. J Med Assoc Thai, 91, 1779-85.
49. Todd DM, Miller JM, Rubin AD, DeBari VA (1992). Amplification of the c-erbB-2 oncogene in breast cancer and its relationship to estrogen and progesterone receptors. Diagn Oncol, 2, 313-17.
50. Wolfson A, Sightler S, Markoe A, et al (1992). The prognostic significance of surgical staging for carcinoma of the endometrial. Gynecol Oncol, 45, 142-6.